-       Report 
- August 2025
-  198 Pages 
- Global 
   From       €3171EUR$3,545USD£2,789GBP 
      €3523EUR$3,939USD£3,099GBP 
          -       Report 
- July 2025
-  350 Pages 
- Global 
   From       €4427EUR$4,949USD£3,894GBP 
          -       Report 
- June 2025
-  150 Pages 
- Global 
   From       €2414EUR$2,699USD£2,124GBP 
          -       Report 
- June 2025
-  400 Pages 
- Global 
   From       €4427EUR$4,949USD£3,894GBP 
          -       Report 
- July 2022
-  203 Pages 
- Global 
   From       €6395EUR$7,150USD£5,626GBP 
             -       Report 
- May 2024
-  135 Pages 
- Global 
   From       €4941EUR$5,524USD£4,346GBP 
      €5813EUR$6,499USD£5,113GBP 
          -       Report 
- January 2023
-  124 Pages 
   From       €3086EUR$3,450USD£2,714GBP 
          -       Report 
- January 2023
-  134 Pages 
- Middle East, Africa 
   From       €3086EUR$3,450USD£2,714GBP 
          -       Report 
- January 2023
-  160 Pages 
- Asia Pacific 
   From       €3086EUR$3,450USD£2,714GBP 
          -       Report 
- January 2023
-  146 Pages 
- North America 
   From       €3086EUR$3,450USD£2,714GBP 
          -       Report 
- January 2023
-  153 Pages 
- Europe 
   From       €3086EUR$3,450USD£2,714GBP 
          -       Report 
- October 2022
-  209 Pages 
- Global 
   From       €3980EUR$4,450USD£3,501GBP 
          -       Report 
- October 2025
-  50 Pages 
- Global 
   From       €2370EUR$2,650USD£2,085GBP 
       
      Solifenacin is a medication used to treat overactive bladder, a condition characterized by urinary urgency, frequency, and incontinence. It is a muscarinic receptor antagonist, meaning it works by blocking the action of a certain chemical in the body that causes bladder contractions. Solifenacin is available in both oral and injectable forms, and is typically prescribed for those who have not responded to other treatments. It is also used to treat urinary retention, a condition in which the bladder    does not empty completely.
Solifenacin is one of several drugs used to treat urological disorders, which include urinary incontinence, urinary tract infections, and kidney stones. Other drugs used to treat these conditions include anticholinergics, alpha-blockers, and 5-alpha reductase inhibitors.
The solifenacin market is highly competitive, with several companies offering generic and branded versions of the drug. Some of the companies in the market include Astellas Pharma, Allergan, Mylan, and Teva Pharmaceuticals. Show Less   Read more